2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
4.810
-0.170 (-3.41%)
Oct 29, 2024, 4:00 PM EDT - Market closed
2seventy bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for 2seventy bio stock have an average target of 10.4, with a low estimate of 5.00 and a high estimate of 18. The average target predicts an increase of 116.22% from the current stock price of 4.81.
Analyst Consensus: Buy
* Price targets were last updated on Jul 29, 2024.
Analyst Ratings
The average analyst rating for 2seventy bio stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +24.74% | Jul 29, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +3.95% | Jun 27, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +128.69% | May 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +149.48% | Apr 8, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +3.95% | Mar 18, 2024 |
Financial Forecast
Revenue This Year
63.99M
from 100.39M
Decreased by -36.26%
Revenue Next Year
78.34M
from 63.99M
Increased by 22.42%
EPS This Year
-1.10
from -4.42
EPS Next Year
-0.42
from -1.10
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 131.5M | 115.2M | 118.1M | ||
| Avg | 64.0M | 78.3M | 102.0M | ||
| Low | 38.5M | 46.4M | 80.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.0% | 80.0% | 50.8% | ||
| Avg | -36.3% | 22.4% | 30.2% | ||
| Low | -61.6% | -27.6% | 2.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.76 | 1.46 | 0.04 | |
| Avg | -1.10 | -0.42 | -0.26 | |
| Low | -1.23 | -1.12 | -0.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.